Ernexa Therapeutics closed at $1.99 on Nov 4, down 1.49%, within 2.7% of its 52-week closing low. Volume of 17.3K shares was 0.29× its 20-day average (below normal).
Split-adjusted performance: -11.0% over one month, -67.1% over six months, -95.2% over one year.
Short interest was 19.9K shares at the Oct 15 settlement (2.1% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ERNAErnexa Therapeutics | $1.99 | −1.49% | −67.1% | — | — | — | $2.3M | |
| REVBRevelation Biosciences | $4.12 | −7.05% | −42.3% | — | — | — | $2.3M | Compare |
| HCWBHCW Biologics | $1.08 | −6.09% | −48.6% | +1969.7% | −11340.3% | — | $2.4M | Compare |
| APVOAptevo Therapeutics | $1.37 | +0.74% | −72.3% | — | — | — | $2.5M | Compare |
| SBFMSunshine Biopharma | $2.65 | −3.28% | −98.8% | −1.6% | −16.9% | — | $2.0M | Compare |
| SILOSilo Pharma | $1.33 | +3.91% | −78.9% | −100.0% | — | — | $2.9M | Compare |
| PPCBPropanc Biopharma | $1.79 | +4.68% | −92.9% | — | — | — | $1.8M | Compare |
| GNPXGenprex | $2.14 | −7.36% | −89.1% | — | — | — | $1.8M | Compare |
| GRIGRI Bio | $1.43 | −7.14% | −39.4% | — | — | — | $3.1M | Compare |
No recent articles focused on Ernexa Therapeutics.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
